Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Thu, February 21, 2013Wed, February 20, 2013Tue, February 19, 2013Mon, February 18, 2013Sun, February 17, 2013Fri, February 15, 2013Thu, February 14, 2013Wed, February 13, 2013Tue, February 12, 2013Mon, February 11, 2013Sun, February 10, 2013Fri, February 8, 2013Thu, February 7, 2013Wed, February 6, 2013Tue, February 5, 2013Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday, February 20, 2013
Published in Health and Fitness on Wednesday, February 13th 2013 at 13:15 GMT by Market Wire
Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday,... -- NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ --
NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: [ DEPO ]) today announced that it will release fourth quarter fiscal year 2012 financial results after the market closes on Wednesday, February 20, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results.
Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at [ http://www.depomed.com ]. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor ® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, [ www.depomed.com ].
CONTACT:
August J. Moretti
Depomed, Inc.
650-462-5900
[ amoretti@depomed.com ]
SOURCE Depomed, Inc.
RELATED LINKS
[ http://www.depomed.com ]
